AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01989585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT01245959 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
Study NCT01245959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
Study NCT01989585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01989585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01989585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo multigated acquisition scan
Study NCT01989585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO
Study NCT01989585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01989585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT01904448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Brainstem Implantation in Children
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01856192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04668079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified cross body stretch
Description: Athlete was in side lying positioned. trunk was moved posteriorly 200 to 300 and shoulder is raised to 900 and semi flex both knees. Athlete was ask to passively pull the humerus across the body into horizontal adduction with the opposite hand.~5 reps once daily 3 sets for 4 weeks was given
Study NCT03126721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979
Description: multiple oral doses of PF-06751979 100 mg a day
Study NCT04668079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sleeper stretch
Description: Athlete was in side lying positioned on the involved side, trunk was rolled posteriorly 200 to 300 and shoulder is raised to 900 and elbow is flexed to 900 and semiflex both knees. athlete was ask to perform internal rotation passively by using the opposite arm.~5 reps once daily 3 sets for 4 weeks was given
Study NCT00027066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Aspirin
Description: 325mg tablet daily
Study NCT00974402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
Study NCT04260984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided injection
Description: For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
Study NCT04260984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: palpation-guided injection
Description: Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
Study NCT00737997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
Study NCT00737997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 ml saline alone
Study NCT00226746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and gemcitabine
Description: Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36.
Study NCT00881972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: walking/running/cycling
Study NCT01150500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-4107 Zotarolimus-Eluting Coronary Stent
Study NCT01313299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Study NCT01313299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Study NCT01313299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Study NCT02433392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CM-BC2
Description: CM-BC2 is a drug-eluting bead, a drug-device combination
Study NCT05110651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels > 2000ng/ml
Study NCT04083690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprogramming of CRT Device Settings to Optimal Electrical Synchrony
Description: Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
Study NCT04083690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reprogramming of CRT Device Settings to Optimal Electrical Synchrony
Description: Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
Study NCT02592928 — intervention group
Intervention type: OTHER
Intervention: Inclusion of Spirometry into the Electronic Health Records
Description: Inclusion of the Forced Spirometry into the Electronic Health Records
Study NCT01856192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00027066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Warfarin
Description: 2mg scored tablet daily
Study NCT00027066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin placebo
Description: 325mg aspirin placebo pill
Study NCT00027066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin placebo
Description: 2mg scored placebo tablet
Study NCT02488070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Part of PET/CT scan
Study NCT02488070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)
Description: Intravenously-administered (IV) radioisotope
Study NCT02488070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Part of PET/MRI scan
Study NCT02488070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Part of PET/CT and/or PET/MRI scans
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT02590549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Collagen Crosslinking
Description: Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.~After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,
Study NCT02590549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ufalink
Description: UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
Study NCT03482453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.
Study NCT01856192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01856192 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01856192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02287935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limberg flap
Description: Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
Study NCT02287935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Karydakis procedure
Description: Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
Study NCT00934466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2637
Description: Single dose of 120 mg MK2637 capsules in one of five treatment periods.
Study NCT00934466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK2637
Description: Single dose of 50 mg MK2637 capsules in one of five treatment periods.
Study NCT00934466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single dose of placebo only in one of five treatment periods.
Study NCT00934466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Dextromethorphan
Description: Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
Study NCT00934466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Dextromethorphan
Description: Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
Study NCT03776981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Activation
Description: Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
Study NCT03776981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization
Description: Six-week core stabilization program for the group of participants with knee osteoarthritis.
Study NCT03569280 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enzalutamide or Abiraterone or Apalutamid
Description: Antitumor treatment
Study NCT01909310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: head extension
Description: the lungs are ventilated with the patient´s head extended
Study NCT01909310 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: head extension
Description: the lungs are ventilated with the patient´s head extended
Study NCT01909310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neutral position
Description: the lungs are ventilated with the patient´s head in neutral position
Study NCT01909310 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: neutral position
Description: the lungs are ventilated with the patient´s head in neutral position
Study NCT01909310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anaesthesiologist´s position
Description: the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
Study NCT01909310 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: anaesthesiologist´s position
Description: the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
Study NCT03482453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-788 placebo-matching capsules.
Study NCT04089332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Eligible subjects will undergo MRI scanning before and after oral glucose tolerance test.
Study NCT04089332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla MRI
Description: A 3 Tesla MRI will be used to assess brain structure, quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits.
Study NCT00827827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise- Stretching Control
Description: 3x per week upper and lower body stretching mixed with active and passive range of motion exercises
Study NCT03562299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPure™ XT
Description: A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
Study NCT03619161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bubbles
Description: All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)
Study NCT03619161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bleach and Bubbles
Description: All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
Study NCT00261729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: paroxetine 20 mg
Study NCT00261729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Prazosin
Study NCT00261729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study NCT01692171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin, Low-Molecular-Weight
Description: single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Study NCT01692171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Study NCT02591784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
Study NCT02591784 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
Study NCT03437759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: exosomes derived from mesenchymal stem cells (MSC-Exo)
Description: After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .
Study NCT03421652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
Study NCT03421652 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
Study NCT04572620 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: 375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
Study NCT04572620 — intervention group
Intervention type: DRUG
Intervention: Abatacept
Description: 10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
Study NCT02526264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Description: Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
Study NCT01761526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
Study NCT03482453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 DiC.
Study NCT00054353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00054353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00054353 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00054353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00054353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO
Study NCT00054353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo reduced-intensity allogeneic PBSCT
Study NCT00054353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo reduced-intensity allogeneic PBSCT
Study NCT00054353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04089332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous Catheter
Description: A blood sampling IV catheter will be used to draw blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin.
Study NCT03843229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini injection
Description: The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
Study NCT03843229 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transarterial Chemoembolization(TACE)
Description: TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
Study NCT03843229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization(TACE)
Description: TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
Study NCT03843229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinobufacini tablet
Description: The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.